Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1996 Jul 6;313(7048):36-9.
doi: 10.1136/bmj.313.7048.36.

Trials to assess equivalence: the importance of rigorous methods

Affiliations

Trials to assess equivalence: the importance of rigorous methods

B Jones et al. BMJ. .

Erratum in

  • BMJ 1996 Aug 31;313(7056):550

Abstract

The aim of an equivalence trial is to show the therapeutic equivalence of two treatments, usually a new drug under development and an existing drug for the same disease used as a standard active comparator. Unfortunately the principles that govern the design, conduct, and analysis of equivalence trials are not as well understood as they should be. Consequently such trials often include too few patients or have intrinsic design biases which tend towards the conclusion of no difference. In addition the application of hypothesis testing in analysing and interpreting data from such trials sometimes compounds the drawing of inappropriate conclusions, and the inclusion and exclusion of patients from analysis may be poorly managed. The design of equivalence trials should mirror that of earlier successful trials of the active comparator as closely as possible. Patient losses and other deviations from the protocol should be minimised; analysis strategies to deal with unavoidable problems should not centre on an "intention to treat" analysis but should seek to show the similarity of results from a range of approaches. Analysis should be based on confidence intervals, and this also carries implications for the estimation of the required numbers of patients at the design stage.

PubMed Disclaimer

Comment in

  • Placebo mania.
    Rothman KJ. Rothman KJ. BMJ. 1996 Jul 6;313(7048):3-4. doi: 10.1136/bmj.313.7048.3a. BMJ. 1996. PMID: 8664770 Free PMC article. No abstract available.

Similar articles

Cited by

References

    1. Cancer Treat Rep. 1978 Jul;62(7):1037-40 - PubMed
    1. N Engl J Med. 1994 Aug 11;331(6):394-8 - PubMed
    1. Science. 1995 Jan 6;267(5194):25-6 - PubMed
    1. BMJ. 1995 May 20;310(6990):1279 - PubMed
    1. BMJ. 1995 Jul 1;311(6996):1-2 - PubMed